VHL expression level in the pathological tissue is significantly associated with clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer patients. (withdrawn 03/11/2021)

  • yejun Cao East Hospital, Tongji University School of Medicine
  • Lingwei Wang
  • Qiying Zhang
  • Yang Han
  • Liang Ma
  • Jie Liu
  • Jinyi Wang
  • Zhengliang Sun
  • Tian Zhao
  • Guohan Chen
  • Xuan Hong

Abstract

Objective  To investigate the association between expression level of VHL in pathological tissue and outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.  Methods  The pathological samples of NSCLC patients were obtained for immunohistochemical staining to evaluate the expression level of VHL. Furthermore, their clinical data were collected and prognosis was traced by phone. The correlation between gene expression level and the hematotoxicity was evaluated by chi-square test. The influence of VHL expression level on the risk of hematotoxicity was tested by logistic regression model. The survival curve was plotted by Kaplan-Meier method and the survival rate between the two groups was compared by log-rank test.  Results  A total of 110 NSCLC patients were enrolled in this study, the median follow-up time of these patients was 27.5 months. In the whole group, 31 patients had died by the last date of follow-up to get their survival information (Nov.10,2020), with a median survival time of 24.3 months. Though immunohistochemical analysis,we found that 59 patients(53.6%) had weak expression level of VHL or lack of expression in their tumor tissues,while 51 patients(46.4%) presented moderate or high expression. We found that the patients with weak expression of VHL in their carcinoma tissue or lack of expression had more opportunities to occur neutropenia after platinum-based chemotherapy(OR=0.264,95%CI=0.085-0.818,P-value=0.021).And the expression level of VHL was correlated with OS(Logrank test:P-value= 0.007,HR= 4.219,95%CI: 1.75-10.174, P-value=0.001), while not related with DFS(Logrank test:P-value=0.256,HR= 1.334,95%CI:0.642-2.769, P-value=0.440).  Conclusion The expression level of VHL gene in pathological tissue is related with Granulocytosis and leukocytotoxicity after platinum-based chemotherapy in NSCLC patients. It can be used as a biomarker to predict the risk of neutropenia and the prognosis of NSCLC patients.

Downloads

Download data is not yet available.

References

1. Chen J, Yin J, Li X, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int J Mol Sci 2014;15:21011-27.
2. Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res 2015;27:1.
3. Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 2016;539:112-7.
4. Han Y, Liu J, Sun M, et al. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis. Dis Markers 2016;2016:7643981.
5. Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 2016;116:3436-86.
6. Du W, Zhang L, Brett-Morris A, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun 2017;8:1769.
7. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015;15:55-64.
8. Kang MR, Park KH, Lee CW, et al. Small activating RNA induced expression of VHL gene in renal cell carcinoma. Int J Biochem Cell Biol 2018;97:36-42.
9. Lenglet M, Robriquet F, Schwarz K, et al. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood 2018;132:469-83.
10. Li S, Rodriguez J, Li W, et al. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proc Natl Acad Sci U S A 2019;116:16997-7006.
11. Lv C, Bai Z, Liu Z, et al. Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms. Int J Clin Exp Pathol 2015.
12. Qian CY, Zheng Y, Wang Y, et al. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer 2016;35:85.
13. Tarade D, Ohh M. The HIF and other quandaries in VHL disease. Oncogene 2018;37:139-47.
14. Wang WC, Tsou MH, Chen HJ,et al.Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma. BMC Res Notes 2014;7:638.
15. Chen G, Zhou J, Chen J, et al. VHL regulates NEK1 via both HIF-2alpha pathway and ubiquitin-proteasome pathway in renal cancer cell. Biochem Biophys Res Commun 2019;509:797-802.
16. Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 2016;539:112-7.
17. Ding XF, Zhou J, Chen G, Wu YL. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells. Mol Med Rep 2018;18:1206-10.
18. Wu K, House L, Liu W,et al. ersonalized targeted therapy for lung cancer. Zhongguo Fei Ai Za Zhi 2013;16:C21-34.
19. Wu K, House L, Liu W,et al. Personalized targeted therapy for lung cancer. Chin J Lung Cancer 2013;16:C21-34.
20. Yin JY, Li X, Li XP, et al. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. Cancer Lett 2016;377:65-73.
21. Zhao X, Wang X, Wu W, et al. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy. Cancer 2012;118:3587-98.
22. Wu DM , Deng SH , Liu T,et al. TGF-β-mediated exosomal lnc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression. Cancer Med. 2018 Oct;7(10):5118-5129.
23. Zhao YS,Le Y,Wang SF,et al. The relationship between EGFR gain and VHL loss in lung adenocarcinoma and poor patient survival. Int J Clin Oncol. 2011 Dec;16(6):679-85
Published
2021-02-20
How to Cite
CAO, yejun et al. VHL expression level in the pathological tissue is significantly associated with clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer patients. (withdrawn 03/11/2021). Diagnostic Pathology, [S.l.], v. 6, n. 1, feb. 2021. ISSN 2364-4893. Available at: <https://www.diagnosticpathology.eu/content/index.php/dpath/article/view/283>. Date accessed: 20 apr. 2021. doi: https://doi.org/10.17629/www.diagnosticpathology.eu-2020-6:283.
Section
Research